Palisade Bio Announces Cancellation of Special Meeting of Stockholders
Palisade Bio (Nasdaq: PALI) announced on October 9, 2025 that it has cancelled its previously adjourned special meeting of stockholders that had been scheduled to reconvene on October 10, 2025. The meeting was earlier reconvened on September 26, 2025 but adjourned without business due to a lack of quorum.
The company said it still has not received sufficient proxies to constitute a quorum and has withdrawn from stockholder consideration the proposals included in its definitive proxy statement filed with the SEC on August 18, 2025.
Palisade Bio (Nasdaq: PALI) ha annunciato il 9 ottobre 2025 che ha annullato la riunione speciale degli azionisti precedentemente rinviata che era prevista per riprendere il 10 ottobre 2025. La riunione era stata riunita in precedenza il 26 settembre 2025, ma rinviata senza deliberazioni a causa di una mancanza di quorum.
L'azienda ha dichiarato di non aver ancora ricevuto prove sufficienti per costituire un quorum e ha ritirato dall'esame degli azionisti le proposte incluse nella sua dichiarazione proxy definitiva presentata alla SEC il 18 agosto 2025.
Palisade Bio (Nasdaq: PALI) anunció el 9 de octubre de 2025 que ha cancelado su reunión especial de accionistas previamente aplazada que había sido programada para reanudarse el 10 de octubre de 2025. La reunión ya se reanudó el 26 de septiembre de 2025 pero fue suspendida sin asuntos por falta de quórum.
La empresa dijo que aún no ha recibido suficientes poderes para constituir un quórum y ha retirado de la consideración de los accionistas las propuestas incluidas en su declaración proxy definitiva presentada ante la SEC el 18 de agosto de 2025.
Palisade Bio (Nasdaq: PALI)는 2025년 10월 9일에 이미 연기되었던 주주 특별주총회를 2025년 10월 10일에 재개하려는 계획을 취소했다고 발표했습니다. 회의는 2025년 9월 26일에 다시 소집되었으나 quorum 부족으로 의결 사안 없이 연기되었습니다.
회사는 여전히 의결정족수를 구성할 충분한 위임장을 받지 못했다고 밝히고, 2025년 8월 18일에 SEC에 제출된 확정 프록시 진술서에 포함된 제안에 대해 주주들의 심사를 주주 고려에서 철회했습니다.
Palisade Bio (Nasdaq : PALI) a annoncé le 9 octobre 2025 qu'elle a annulé sa réunion extraordinaire des actionnaires, auparavant ajournée, qui devait se réunir à nouveau le 10 octobre 2025. La réunion avait été réunie plus tôt le 26 septembre 2025 mais ajournée sans affaires en raison d'un manque de quorum.
La société a déclaré qu'elle n'avait toujours pas reçu suffisamment de procurations pour constituer un quorum et a retiré de l'examen des actionnaires les propositions incluses dans sa déclaration proxy définitive déposée auprès de la SEC le 18 août 2025.
Palisade Bio (Nasdaq: PALI) kündigte am 9. Oktober 2025 an, dass es seine zuvor vertagte Sonderversammlung der Aktionäre abgesagt hat, die am 10. Oktober 2025 wieder einberufen werden sollte. Die Versammlung wurde zuvor am 26. September 2025 wieder einberufen, jedoch ohne Geschäft aufgrund von quorum-Mangel vertagt.
Das Unternehmen sagte, dass es noch nicht ausreichende Vollmachten erhalten hat, um ein Quorum zu bilden, und hat die im endgültigen Proxy-Dokument vom 18. August 2025 enthaltenen Vorschläge von der Berücksichtigung der Aktionäre zurückgezogen.
أعلنت Palisade Bio (الرمز في ناسداك: PALI) في 9 أكتوبر 2025 أنها ألغت اجتماع المساهمين الخاص المؤجل من قبل والذي كان مقرراً أن يعقد مرة أخرى في 10 أكتوبر 2025. كان الاجتماع قد أعيد جمعه مسبقاً في 26 سبتمبر 2025 ولكنه أُجّل دون عقد أعمال بسبب نقص النصاب.
وقالت الشركة إنها لم تتلقَّ حتى الآن تفويضات كافية لتكوين نصاب، كما أنها سَحبت من اعتبار المساهمين المقترحات الواردة في بيان وكالات التصويت النهائي المقدم إلى هيئة الأوراق المالية في 18 أغسطس 2025.
Palisade Bio（纳斯达克股票代码：PALI）在2025年10月9日宣布，已取消原本已被推迟的股东特别会议，该会议原定于2025年10月10日重新召开。该会议此前于2025年9月26日重新召集，但因缺乏法定人数而无议题而休会。
公司表示，至今尚未收到足以构成法定人数的代理授权，且已将其于2025年8月18日向美国证券交易委员会提交的最终代理声明中所列提案从股东审议中撤回。
- None.
- Special meeting scheduled for Oct 10, 2025 cancelled
- Company withdrew proposals filed on Aug 18, 2025 from stockholder consideration
- Meeting reconvened on Sept 26, 2025 adjourned due to lack of quorum
Carlsbad, CA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Company determined to cancel its previously adjourned special meeting of stockholders (the “Special Meeting”), which had been scheduled to reconvene on Friday, October 10, 2025, at 10:00 a.m. Pacific Time.
The Special Meeting was previously adjourned to, and reconvened on, September 26, 2025, but was adjourned again without any business being conducted, due to the lack of the required quorum as of the meeting time. As of today, the Company has still not received proxies that would constitute a quorum and has decided to cancel the Special Meeting and to withdraw from consideration by the Company’s stockholders the proposals set forth in the definitive proxy statement filed with the U.S. Securities and Exchange Commission on August 18, 2025.
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
FAQ
Why did Palisade Bio (PALI) cancel the special meeting scheduled for October 10, 2025?
What proposals were withdrawn by Palisade Bio (PALI) after cancelling the October 2025 special meeting?
When was the special meeting of Palisade Bio (PALI) previously reconvened and adjourned?
Will Palisade Bio (PALI) reschedule the cancelled special meeting?
How does the lack of quorum affect Palisade Bio (PALI) stockholders?
